Save time and get answers to complex questions with AI chat
Dabrafenib patent expiration date novartis gsk composition matter?What excipients are combined with ruxolitinib in apotex's medication?Drugpatentwatch market analysis industry today?Bortezomib market france?Quartette side effects?
See the DrugPatentWatch profile for Tremfya
Tremfya (guselkumab) was approved by the FDA in July 2017 for adults with moderate-to-severe plaque psoriasis. If you’d like, I can look up the exact calendar date.
Other Questions About Tremfya :